2023 Q2 Form 10-Q Financial Statement
#000149315223016642 Filed on May 12, 2023
Income Statement
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|---|---|---|
Revenue | $9.000K | $10.00K | $5.000K |
YoY Change | -25.0% | 100.0% | -91.07% |
Cost Of Revenue | $5.000K | $1.000K | $1.000K |
YoY Change | -16.67% | 0.0% | -66.67% |
Gross Profit | $4.000K | $9.000K | $4.000K |
YoY Change | -33.33% | 125.0% | -92.45% |
Gross Profit Margin | 44.44% | 90.0% | 80.0% |
Selling, General & Admin | $1.730M | $1.993M | $1.660M |
YoY Change | 29.3% | 20.06% | -17.9% |
% of Gross Profit | 43250.0% | 22144.44% | 41500.0% |
Research & Development | $160.0K | $174.0K | $363.0K |
YoY Change | -38.22% | -52.07% | 24.74% |
% of Gross Profit | 4000.0% | 1933.33% | 9075.0% |
Depreciation & Amortization | $32.00K | $33.00K | $33.00K |
YoY Change | -3.03% | 0.0% | 0.0% |
% of Gross Profit | 800.0% | 366.67% | 825.0% |
Operating Expenses | $1.890M | $2.167M | $2.056M |
YoY Change | 18.35% | 5.4% | -12.36% |
Operating Profit | -$1.886M | -$2.158M | -$2.052M |
YoY Change | 18.54% | 5.17% | -10.51% |
Interest Expense | $792.0K | $1.100M | -$571.0K |
YoY Change | -191.77% | -292.64% | 134.98% |
% of Operating Profit | |||
Other Income/Expense, Net | -$793.0K | -$1.127M | -$84.00K |
YoY Change | -22.78% | 1241.67% | -119.22% |
Pretax Income | -$2.679M | -$3.285M | -$2.707M |
YoY Change | 2.33% | 21.35% | 35.83% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$2.669M | -$3.277M | -$2.706M |
YoY Change | 1.95% | 21.1% | 29.6% |
Net Earnings / Revenue | -29655.56% | -32770.0% | -54120.0% |
Basic Earnings Per Share | -$0.07 | $0.77 | |
Diluted Earnings Per Share | -$0.07 | -$0.09 | -$71.32K |
COMMON SHARES | |||
Basic Shares Outstanding | 37.95M shares | 37.95M shares | 37.94M shares |
Diluted Shares Outstanding | 37.95K shares | 8.569M shares |
Balance Sheet
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $261.0K | $280.0K | $448.0K |
YoY Change | -62.82% | -37.5% | -44.62% |
Cash & Equivalents | $261.0K | $280.0K | $448.0K |
Short-Term Investments | |||
Other Short-Term Assets | $1.083M | $1.461M | $1.381M |
YoY Change | 7.12% | 5.79% | 7.47% |
Inventory | |||
Prepaid Expenses | |||
Receivables | $6.000K | $6.000K | |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $1.350M | $1.747M | $1.829M |
YoY Change | -21.74% | -4.48% | -14.61% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | |||
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | $673.0K | $705.0K | |
YoY Change | -16.29% | ||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $50.00K | $50.00K | $50.00K |
YoY Change | 0.0% | 0.0% | 0.0% |
Total Long-Term Assets | $10.93M | $10.78M | $887.0K |
YoY Change | 1179.51% | 1115.78% | -12.87% |
TOTAL ASSETS | |||
Total Short-Term Assets | $1.350M | $1.747M | $1.829M |
Total Long-Term Assets | $10.93M | $10.78M | $887.0K |
Total Assets | $12.28M | $12.53M | $2.716M |
YoY Change | 376.04% | 361.38% | -14.05% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $506.0K | $707.0K | $501.0K |
YoY Change | 214.29% | 41.12% | 35.41% |
Accrued Expenses | $256.0K | $359.0K | $596.0K |
YoY Change | -50.86% | -39.77% | -28.02% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $22.94M | $20.04M | $6.657M |
YoY Change | 229.26% | 201.07% | 229.55% |
Total Short-Term Liabilities | $24.51M | $22.53M | $10.10M |
YoY Change | 169.73% | 123.04% | 157.04% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $10.07M | $10.01M | $4.208M |
YoY Change | 49.02% | 137.9% | -21.11% |
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $10.07M | $10.01M | $4.208M |
YoY Change | 49.02% | 137.9% | -21.11% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $24.51M | $22.53M | $10.10M |
Total Long-Term Liabilities | $10.07M | $10.01M | $4.208M |
Total Liabilities | $34.57M | $32.54M | $14.26M |
YoY Change | 118.25% | 128.11% | 54.66% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$122.2M | -$119.5M | |
YoY Change | 10.02% | ||
Common Stock | $4.000K | $4.000K | |
YoY Change | 0.0% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$22.18M | -$19.89M | -$11.55M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $12.28M | $12.53M | $2.716M |
YoY Change | 376.04% | 361.38% | -14.05% |
Cashflow Statement
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$2.669M | -$3.277M | -$2.706M |
YoY Change | 1.95% | 21.1% | 29.6% |
Depreciation, Depletion And Amortization | $32.00K | $33.00K | $33.00K |
YoY Change | -3.03% | 0.0% | 0.0% |
Cash From Operating Activities | -$2.019M | -$1.865M | -$1.636M |
YoY Change | 15.64% | 14.0% | -37.79% |
INVESTING ACTIVITIES | |||
Capital Expenditures | |||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | -$10.00M | $0.00 |
YoY Change | -100.0% | ||
Cash From Investing Activities | $0.00 | -$10.00M | |
YoY Change | |||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $0.00 | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 2.000M | $11.50M | 1.500M |
YoY Change | 0.0% | 666.67% | -39.9% |
NET CHANGE | |||
Cash From Operating Activities | -2.019M | -$1.865M | -1.636M |
Cash From Investing Activities | 0.000 | -$10.00M | |
Cash From Financing Activities | 2.000M | $11.50M | 1.500M |
Net Change In Cash | -19.00K | -$365.0K | $0.00 |
YoY Change | -107.48% | -100.0% | |
FREE CASH FLOW | |||
Cash From Operating Activities | -$2.019M | -$1.865M | -$1.636M |
Capital Expenditures | |||
Free Cash Flow | -$1.865M | ||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001708599 | |
CY2023Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2023Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023Q1 | us-gaap |
Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
|
http://fasb.org/us-gaap/2023#RelatedPartyMember | |
CY2022Q4 | us-gaap |
Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
|
http://fasb.org/us-gaap/2023#RelatedPartyMember | |
CY2023Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
CY2022Q1 | AGE |
Payment To Acquire Loan Facilities
PaymentToAcquireLoanFacilities
|
usd | |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
usd | |
CY2021Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
usd | |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
shares | |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
||
CY2021Q4 | AGE |
Warrant Liability
WarrantLiability
|
usd | |
CY2022 | AGE |
Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
|
usd | |
CY2022 | AGE |
Unrealized Loss On Change On Other Than Options
UnrealizedLossOnChangeOnOtherThanOptions
|
shares | |
CY2022 | AGE |
Unrealized Loss On Change In Fair Value Of Warrants Per Share
UnrealizedLossOnChangeInFairValueOfWarrantsPerShare
|
||
CY2023Q1 | AGE |
Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
|
usd | |
CY2023Q1 | AGE |
Unrealized Loss On Change On Other Than Options
UnrealizedLossOnChangeOnOtherThanOptions
|
shares | |
CY2023Q1 | AGE |
Unrealized Loss On Change In Fair Value Of Warrants Per Share
UnrealizedLossOnChangeInFairValueOfWarrantsPerShare
|
||
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
||
CY2023Q1 | us-gaap |
Accelerated Share Repurchases Final Price Paid Per Share
AcceleratedShareRepurchasesFinalPricePaidPerShare
|
||
CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
||
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
pure | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
pure | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | |
CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
usd | |
CY2023Q1 | us-gaap |
Short Term Debt Refinanced Amount
ShortTermDebtRefinancedAmount
|
usd | |
CY2023Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2023Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2023Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-03-31 | |
CY2023Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023Q1 | dei |
Entity File Number
EntityFileNumber
|
1-38519 | |
CY2023Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
AgeX Therapeutics, Inc. | |
CY2023Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
82-1436829 | |
CY2023Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1101 Marina Village Parkway | |
CY2023Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 201 | |
CY2023Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Alameda | |
CY2023Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 per share | |
CY2023Q1 | dei |
Trading Symbol
TradingSymbol
|
AGE | |
CY2023Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NYSEAMER | |
CY2023Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2023Q1 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | |
CY2023Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
37951261 | shares |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
280000 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
645000 | usd |
CY2023Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6000 | usd |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
4000 | usd |
CY2023Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1461000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1804000 | usd |
CY2023Q1 | us-gaap |
Assets Current
AssetsCurrent
|
1747000 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
2453000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
50000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
50000 | usd |
CY2023Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
705000 | usd |
CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
738000 | usd |
CY2023Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
CY2023Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
94501 | |
CY2023Q1 | dei |
City Area Code
CityAreaCode
|
(510) | |
CY2023Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
671-8370 | |
CY2023Q1 | us-gaap |
Notes And Loans Receivable Gross Noncurrent
NotesAndLoansReceivableGrossNoncurrent
|
10029000 | usd |
CY2023Q1 | us-gaap |
Assets
Assets
|
12531000 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
3241000 | usd |
CY2023Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1262000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1034000 | usd |
CY2023Q1 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
20042000 | usd |
CY2022Q4 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
7646000 | usd |
CY2023Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
144000 | usd |
CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
141000 | usd |
CY2023Q1 | AGE |
Warrant Liability
WarrantLiability
|
347000 | usd |
CY2022Q4 | AGE |
Warrant Liability
WarrantLiability
|
180000 | usd |
CY2023Q1 | AGE |
Insurance Premium Liability And Other Current Liabilities
InsurancePremiumLiabilityAndOtherCurrentLiabilities
|
730000 | usd |
CY2022Q4 | AGE |
Insurance Premium Liability And Other Current Liabilities
InsurancePremiumLiabilityAndOtherCurrentLiabilities
|
1077000 | usd |
CY2023Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
22525000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10078000 | usd |
CY2023Q1 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
10011000 | usd |
CY2022Q4 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
10478000 | usd |
CY2023Q1 | us-gaap |
Liabilities
Liabilities
|
32536000 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
20556000 | usd |
CY2023Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37951000 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37951000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37949000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37949000 | shares |
CY2023Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | usd |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | usd |
CY2023Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
99589000 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
98994000 | usd |
CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-119487000 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-116210000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-19894000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-17212000 | usd |
CY2023Q1 | us-gaap |
Minority Interest
MinorityInterest
|
-111000 | usd |
CY2022Q4 | us-gaap |
Minority Interest
MinorityInterest
|
-103000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-20005000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-17315000 | usd |
CY2023Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
12531000 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
3241000 | usd |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
10000 | usd |
CY2022Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
5000 | usd |
CY2023Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1000 | usd |
CY2022Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1000 | usd |
CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
9000 | usd |
CY2022Q1 | us-gaap |
Gross Profit
GrossProfit
|
4000 | usd |
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
174000 | usd |
CY2022Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
396000 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1993000 | usd |
CY2022Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1660000 | usd |
CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
2167000 | usd |
CY2022Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
2056000 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2158000 | usd |
CY2022Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2052000 | usd |
CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
1100000 | usd |
CY2022Q1 | us-gaap |
Interest Expense
InterestExpense
|
571000 | usd |
CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
30000 | usd |
CY2022Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
87000 | usd |
CY2023Q1 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
3000 | usd |
CY2022Q1 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
3000 | usd |
CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1127000 | usd |
CY2022Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-655000 | usd |
CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-3285000 | usd |
CY2022Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-2707000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-8000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-1000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3277000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2706000 | usd |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
37950000 | shares |
CY2022Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
37942000 | shares |
CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-3285000 | usd |
CY2022Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-2707000 | usd |
CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3285000 | usd |
CY2022Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2707000 | usd |
CY2023Q1 | AGE |
Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations
LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations
|
8000 | usd |
CY2022Q1 | AGE |
Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations
LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations
|
1000 | usd |
CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-3277000 | usd |
CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-2706000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-17315000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
-1000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
526000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
70000 | usd |
CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-3285000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-20005000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-20005000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-11875000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-11875000 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
-1000 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
178000 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
2575000 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
239000 | usd |
CY2022Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-2707000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-11591000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-11591000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3277000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2706000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-8000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-1000 | usd |
CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
30000 | usd |
CY2022Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
87000 | usd |
CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
33000 | usd |
CY2022Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
33000 | usd |
CY2023Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1057000 | usd |
CY2022Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
544000 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
70000 | usd |
CY2022Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
239000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
3000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-25000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-314000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-243000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
205000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
207000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
61000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
19000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
|
-353000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
|
-325000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
6000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-1000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1865000 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1636000 | usd |
CY2023Q1 | AGE |
Payment To Acquire Loan Facilities
PaymentToAcquireLoanFacilities
|
10000000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-10000000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
11500000 | usd |
CY2022Q1 | us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
1500000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
11500000 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1500000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-365000 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-136000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
695000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
634000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
330000 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
498000 | usd |
CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-119500000 | usd |
CY2023Q1 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
300000 | usd |
CY2023Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_84E_eus-gaap--UseOfEstimates_zaM1gxMSKd7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zhfQYYPaI1oi">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of our embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Warrant Liability</i>, for discussion on estimated change in fair value of warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
CY2023Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zuaAiyZJqWZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_znJa8AixCHx4">Concentration of credit risk and other risks and uncertainties</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. To date, AgeX has not experienced any losses on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, <i>Convertible Note Receivable </i>and 5, <i>Related Party Transactions</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
CY2023Q1 | us-gaap |
Secured Debt
SecuredDebt
|
10000000 | usd |
CY2023Q1 | AGE |
Warrant Liability
WarrantLiability
|
347000 | usd |
CY2023Q1 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
105000000 | usd |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
280000 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
645000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
50000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
50000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
330000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
695000 | usd |
CY2023Q1 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P10Y | |
CY2023Q1 | us-gaap |
Lessee Operating Lease Description
LesseeOperatingLeaseDescription
|
(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset | |
CY2023Q1 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.10 | pure |
CY2023Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
1312000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
1312000 | usd |
CY2023Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
607000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
574000 | usd |
CY2023Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
705000 | usd |
CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
738000 | usd |
CY2022Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
33000 | usd |
CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
33000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
98000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
131000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
131000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
132000 | usd |
CY2022Q4 | AGE |
Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
|
213000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
705000 | usd |
CY2023Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
707000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
568000 | usd |
CY2023Q1 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
196000 | usd |
CY2022Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
193000 | usd |
CY2023Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
359000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
273000 | usd |
CY2023Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1262000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1034000 | usd |
CY2023Q1 | us-gaap |
Other Assets
OtherAssets
|
250000 | usd |
CY2020Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
9600657 | shares |
CY2023Q1 | us-gaap |
Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
|
250000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
25000000 | usd |
CY2023Q1 | AGE |
Common Stock Outstanding Percentage
CommonStockOutstandingPercentage
|
0.85 | pure |
CY2023Q1 | us-gaap |
Secured Debt
SecuredDebt
|
10000000 | usd |
CY2023Q1 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
2000000000 | usd |
CY2022 | AGE |
Changes In Fair Value
ChangesInFairValue
|
225000 | usd |
CY2022Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
500000 | usd |
CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
454545 | shares |
CY2022Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.3960 | |
CY2022Q4 | AGE |
Warrant Liability
WarrantLiability
|
180000 | usd |
CY2023Q1 | AGE |
Changes In Fair Value
ChangesInFairValue
|
30000 | usd |
CY2023Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
1000000 | usd |
CY2023Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
756426 | shares |
CY2023Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.4593 | |
CY2023Q1 | AGE |
Warrant Liability
WarrantLiability
|
347000 | usd |
CY2023Q1 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
2000000000 | usd |
CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
30000 | usd |
CY2022Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
87000 | usd |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37951261 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37951261 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37949196 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37949196 | shares |
CY2023Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
14000 | usd |
CY2022Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
7000 | usd |
CY2023Q1 | AGE |
Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
|
2000 | usd |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
70000 | usd |
CY2022Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
239000 | usd |
CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.798 | |
CY2022Q1 | us-gaap |
Accelerated Share Repurchases Final Price Paid Per Share
AcceleratedShareRepurchasesFinalPricePaidPerShare
|
0.798 | |
CY2022Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y6M7D | |
CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.3096 | pure |
CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0162 | pure |
CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2022Q1 | AGE |
Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
|
2000 | usd |
CY2022Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
178000 | usd |
CY2023Q1 | us-gaap |
Assets Fair Value Adjustment
AssetsFairValueAdjustment
|
663000 | usd |
CY2022Q1 | us-gaap |
Assets Fair Value Adjustment
AssetsFairValueAdjustment
|
4103000 | usd |
CY2022Q1 | us-gaap |
Short Term Debt Refinanced Amount
ShortTermDebtRefinancedAmount
|
7160000 | usd |
CY2020Q2 | AGE |
Loss Contingency Description
LossContingencyDescription
|
On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan | |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
2000000 | usd |